A new trading day began on Tuesday, with Cognition Therapeutics Inc (NASDAQ: CGTX) stock price down -6.82% from the previous day of trading, before settling in for the closing price of $0.42. CGTX’s price has ranged from $0.34 to $2.95 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Meanwhile, its annual earnings per share averaged 52.79%. With a float of $50.22 million, this company’s outstanding shares have now reached $59.85 million.
The extent of productivity of a business whose workforce counts for 28 workers is very important to gauge. In terms of profitability, gross margin is 0.0%, operating margin of 0.0%, and the pretax margin is 0.0%.
Cognition Therapeutics Inc (CGTX) Insider Updates
As we move forward, let’s examine how large-scale investors are investing in this stock of the Biotechnology Industry. The insider ownership of Cognition Therapeutics Inc is 18.96%, while institutional ownership is 8.23%. The most recent insider transaction that took place on Jan 31 ’25, was worth 30,001. In this transaction CEO & President of this company bought 38,851 shares at a rate of $0.77, taking the stock ownership to the 38,851 shares.
Cognition Therapeutics Inc (CGTX) Performance Highlights and Predictions
According to the Wall Street analysts, stocks earnings will be around 52.79% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 26.97% during the next five years compared to -16.44% drop over the previous five years of trading.
Cognition Therapeutics Inc (NASDAQ: CGTX) Trading Performance Indicators
Here are Cognition Therapeutics Inc’s current performance indicators. According to the last quarter’s results, the stock had a quick ratio of 2.65.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.86, a number that is poised to hit -0.12 in the next quarter and is forecasted to reach -0.95 in one year’s time.
Technical Analysis of Cognition Therapeutics Inc (CGTX)
The latest stats from [Cognition Therapeutics Inc, CGTX] show that its last 5-days average volume of 0.7 million was inferior to 1.61 million than last year’s volume. As of the previous 9 days, the stock’s Stochastic %D was 11.84%. Additionally, its Average True Range was 0.05.
During the past 100 days, Cognition Therapeutics Inc’s (CGTX) raw stochastic average was set at 3.45%, which indicates a significant increase from 1.91% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 81.07% in the past 14 days, which was lower than the 95.58% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $0.5484, while its 200-day Moving Average is $0.7722. Now, the first resistance to watch is $0.4214. This is followed by the second major resistance level at $0.4507. The third major resistance level sits at $0.4664. If the price goes on to break the first support level at $0.3764, it is likely to go to the next support level at $0.3607. Assuming the price breaks the second support level, the third support level stands at $0.3314.
Cognition Therapeutics Inc (NASDAQ: CGTX) Key Stats
With a market capitalization of 24.30 million, the company has a total of 61,973K Shares Outstanding. Currently, annual sales are 0 K while annual income is -33,970 K. The company’s previous quarter sales were 0 K while its latest quarter income was -7,840 K.
